Renflexis (infliximab-abda)
Provider Summary
Primary Uses
Same reference-product indications as infliximab when prescribed per payer/clinical criteria.
Mechanism of action
Biosimilar to infliximab; anti‑TNF‑α monoclonal antibody effect is comparable at approved indications.
Pre-treatment / baseline requirement
Baseline TB testing and hepatitis B screening; baseline CBC and CMP/LFTs; review history of recurrent infections and heart failure; consider baseline dermatologic exam for skin cancer risk; review vaccination status; pregnancy status when applicable. Infusion reaction preparedness (premeds per ordering clinician).
Common side effects
Infusion reactions, headache, abdominal pain, nausea, upper respiratory infection, rash.
Serious adverse effects / key risks
Boxed warning: serious infections (including TB and invasive fungal/opportunistic infections) and malignancy; HBV reactivation; severe infusion reactions/hypersensitivity; demyelinating disease; worsening heart failure; cytopenias; lupus-like syndrome.
Referral requirements
Standard infusion referral form + drug-specific checklist.
Patient & Caregiver Education
What it treats
Same reference-product indications as infliximab when prescribed
How it works
Blocks TNF (a key inflammatory signal) to reduce inflammation.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Infusion reactions, headache, abdominal pain, nausea, upper respiratory infection, rash.
Get urgent help for
Boxed warning: serious infections and malignancy; HBV reactivation; severe infusion reactions/hypersensitivity; demyelinating disease; worsening heart failure; cytopenias; lupus-like syndrome.
On treatment day
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.